Unilateral retinoblastoma

Summary

Unilateral retinoblastoma (MONDO:0003076) is a disease and 6 clinical trials. Top therapeutic interventions include carboplatin. A subtype of retinoblastoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	unilateral retinoblastoma
Mondo ID	MONDO:0003076
DOID	DOID:4651
NCIT	C8714
UMLS	C0854915
MedGen	208929
GARD	0023355
Is cancer (heuristic)	no

Data availability: 31 cell lines.

Disease family

This is a subtype of retinoblastoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › sensory system cancer › ocular cancer › retinal cancer › retinal cell cancer › retinoblastoma › unilateral retinoblastoma

Related subtypes (6): trilateral retinoblastoma, bilateral retinoblastoma, intraocular retinoblastoma, extraocular retinoblastoma, hereditary retinoblastoma, non-hereditary retinoblastoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE3	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03475121	PHASE3	COMPLETED	Treatment Protocol for Non-Metastatic Unilateral Retinoblastoma
NCT05504291	PHASE2	RECRUITING	A Study to Give Treatment Inside the Eye to Treat Retinoblastoma
NCT02097134	PHASE1	COMPLETED	Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma
NCT03932786	Not specified	RECRUITING	Studying Health Outcomes After Treatment in Patients With Retinoblastoma
NCT04959097	Not specified	RECRUITING	Retinoblastoma Patient Clinical Database and Tissue Repository
NCT06725173	Not specified	RECRUITING	Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra-ocular Metastasis.

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CARBOPLATIN	4	1